Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
26.17
Nov 19 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
2.53B
Enterprise Value
1.72B
Income
-420.01M
Sales
36.53M
Book/sh
11.30
Cash/sh
8.67
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
145
IPO
May 23, 2019
P/E
-
Forward P/E
-
PEG
-
P/S
69.27
P/B
2.32
P/C
3.02
P/FCF
-
EV/EBITDA
-
EV/Sales
47.13
Quick Ratio
9.04
Current Ratio
9.04
Debt/Eq
0.03
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
-4.49
EPS next Y
-4.28
EPS next Q
-1.18
EPS this Y
-270.88%
EPS next Y
9.93%
EPS next 5Y
-
EPS past 3/5Y
3.17% 1.64%
Sales past 3/5Y
62.54% 62.11%
EPS Y/Y TTM
-144.53%
Sales Y/Y TTM
-82.99%
EPS Q/Q
-191.88%
Sales Q/Q
-95.07%
Insider Own
6.64%
Insider Trans
-0.56%
Inst Own
101.96%
Inst Trans
5.12%
ROA
-34.98%
ROE
-38.46%
ROIC
-37.51%
Gross Margin
87.67%
Oper. Margin
-1267.38%
Profit Margin
-1149.62%
SMA20
-16.57%
SMA50
-24.33%
SMA200
-22.42%
Trades
Shs Outstand
96.65M
Shs Float
90.27M
52W High
42.68 -38.68%
52W Low
25.75 1.63%
Volatility
8.95% 5.72%
ATR (14)
1.75
RSI (14)
26.41
Beta
0.18
Rel Volume
0.00
Avg Volume
940.18K
Volume
0
Perf Week
-16.89%
Perf Month
-26.22%
Perf Quarter
-34.03%
Perf Half Y
-11.41%
Perf YTD
-24.30%
Perf Year
-21.01%
Perf 3Y
-13.83%
Perf 5Y
12.70%
Perf 10Y
-
Prev Close
26.17
Price
26.17
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$50.15
Implied Upside
+91.6%
Analysts17incl. previous ratings
Rating Distribution15 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 16, 2026Initiated
WWilliam Blair
Outperform
Oct 14, 2026Resumed
SF logoSStifel
Buy$48+83.4%
Jan 07, 2026Resumed
UBS logoUUBS
Buy$50+91.1%
Nov 24, 2025Initiated
TFC logoTTruist
Buy
Sep 18, 2025Initiated
GGuggenheim
Buy$50+91.1%
Sep 04, 2025Initiated
CCitizens JMP
Mkt Outperform$41+56.7%
Sep 04, 2025Initiated
BCS logoBBarclays
Overweight$40+52.8%
Jul 22, 2025Initiated
TD logoTTD Cowen
Buy
Jul 10, 2025Resumed
GS logoGGoldman
Neutral$25-4.5%
Jun 26, 2025Initiated
WFC logoWWells Fargo
Overweight$44+68.1%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hata Yujiro SPresident and CEOOct 06 '26Option Exercise4.3126,338113,517717,033Oct 08 07:03 PM
Hata Yujiro SPresident and CEOOct 06 '26Sale37.4126,338985,397690,695Oct 08 07:03 PM
YUJIRO HATACEOOct 06 '26Proposed Sale38.23230,3168,804,981Oct 06 04:13 PM
Ruiz Briseno AndresChief Accounting OfficerJul 07 '26Option Exercise12.869,550122,81336,016Jul 09 04:56 PM
Ruiz Briseno AndresChief Accounting OfficerJul 07 '26Sale40.019,550382,13126,466Jul 09 04:56 PM
Andres Ruiz BrisenoSenior VPJul 07 '26Proposed Sale40.019,550382,131Jul 07 04:54 PM
Stein JeffreyDirectorMar 02 '26Buy32.9650,0001,647,89054,281Mar 02 07:18 PM
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
FounderMr. Yujiro S. Hata
Ph.D.Dr. Joshua Bleharski M.B.A.
Chief Accounting OfficerMr. Andres Ruiz Briseno CPA
Chief Legal OfficerMr. Douglas B. Snyder
President of Research & DevelopmentDr. Michael A. White Ph.D.